Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Fulphila | 10 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1886.10 | Biological · Prescription | Biosimilar Collaborations Ireland Limited (BCIL) | Valid |
| Grasustek 6 mg per 0.6 ml | 10 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1765.65 | Biological · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| NEUCYTE | 10 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1765.65 | Biological · Prescription | Biocon Biologics Limited | Valid |
| NEULASTIM 6MG-0.6ML PRE-FILLED SYRINGE | 6 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 2568.25 | NCE · Prescription | KYOWA KIRIN LIMITED | Valid |
| Neulasta Onpro | 6 mg | Solution for injection in pre-filled syringe · Subcutaneous use | 1 Pre-filled syringe | SAR 3531.35 | Biological · Prescription | KYOWA KIRIN LIMITED | Valid |
| Nyvepria | 10 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1765.65 | Biological · Prescription | Pfizer Europe MA EEIG | Valid |
| Pelgraz 6 mg in 0.6 ml | 10 mg/ml | Solution for injection in pre-filled syringe · Subcutaneous use | 1 Pre-filled syringe | SAR 1765.65 | Biological · Prescription | Boston Oncology Arabia | Valid |
| Ziextenzo | 6 mg | Solution for injection in pre-filled syringe · Subcutaneous use | 1 Pre-filled syringe | SAR 2095.70 | Biological · Prescription | Sandoz GmbH | Valid |
| NEULASTIM 6MG-0.6ML PRE-FILLED SYRINGE | 10 mg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 6100.70 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
SOFT TISSUE SARCOMA - LEIOMYOSARCOMA & LIPOSARCOMA-ADVERSE REACTION MANAGEMENT; THYROID CANCER-MEDULLARY CARCINOMA-SUPPORTIVE CARE
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NEULASTA | 6MG/0.6ML | syringe | AMGEN | Prescription | 31 Jan 2002 |
| FULPHILA | 6MG/0.6ML | injectable · injection | MYLAN GMBH | Prescription | 4 Jun 2018 |
| UDENYCA | 6MG/0.6ML | injectable · injection | COHERUS BIOSCIENCES INC | Prescription | 2 Nov 2018 |
| ZIEXTENZO | 6MG/0.6ML | injectable · injection | SANDOZ INC | Prescription | 4 Nov 2019 |
| NYVEPRIA | 6MG/0.6ML | injectable · injection | HOSPIRA INC | Prescription | 10 Jun 2020 |
| FYLNETRA | 6MG/0.6ML | injectable · injection | KASHIV BIOSCIENCES LLC | Prescription | 26 May 2022 |
| STIMUFEND | 6MG/0.6ML | solution · injection | FRESENIUS KABI USA | Prescription | 1 Sep 2022 |
| ARMLUPEG | 6MG/0.6ML | injection · solution | LUPIN LTD | Prescription | 28 Nov 2025 |
| ENNUMO | 6MG/0.6ML | injectable · subcutaneous | ACCORD BIOPHARMA INC. | Prescription | 7 May 2026 |
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
To reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Treatment of neutropenia
Treatment of neutropenia
Reducing neutropenia in patients taking cancer treatments
Treatment of neutropenia
Treatment of neutropenia.
Treatment of neutropenia.
Treatment of neutropenia
Treatment of neutropenia.
Reduction of neutropoenia in adults
5 more — full table
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| FULPHILA | 02484153 | 10 MG / ML | SOLUTION · SUBCUTANEOUS | BIOCON BIOLOGICS CANADA INC |
| LAPELGA | 02474565 | 6 MG / 0.6 ML | SOLUTION · SUBCUTANEOUS | APOTEX INC |
| LAPELGA | 02529343 | 6 MG / 0.6 ML | SOLUTION · SUBCUTANEOUS | APOTEX INC |
| NEULASTA | 02249790 | 10 MG / ML | SOLUTION · SUBCUTANEOUS | AMGEN CANADA INC |
| NIOPEG | 02546973 | 6 MG / 0.6 ML | SOLUTION · SUBCUTANEOUS | NORA PHARMA INC |
| NYVEPRIA | 02506238 | 6 MG / 0.6 ML | SOLUTION · SUBCUTANEOUS | PFIZER CANADA ULC |
| PEXEGRA | 02553945 | 10 MG / ML | SOLUTION · SUBCUTANEOUS | JAMP PHARMA CORPORATION |
| ZIEXTENZO | 02497395 | 6 MG / 0.6 ML | SOLUTION · SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FULPHILA 6 MG/0.6 ML SYRINGE | $3369.51 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.